Transgenomic, Inc. 

(Public, OTC:TBIO)   Watch this stock   
Find more results for TBIO
Nov 5, 2009
Q3 2009 Earnings Conference Call
Nov 5, 2009
Q3 2009 Earnings Release
  

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -7.25% -2.06%
Operating margin -7.93% -1.53%
EBITD margin - 1.38%
Return on average assets -9.34% -2.70%
Return on average equity -12.55% -3.63%
Employees 119 -

Address

12325 Emmet Street
Omaha, NE 68164
United States - Map
+1-402-4525400 (Phone)
+1-402-4525401 (Fax)

Website links

Transgenomic, Inc. discussed on blogs

Ranking All OTC Stocks by Weekly Performance - NASD100.com - Daily ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 17 hours ago

Transgenomic, Inc. discussions

  View all discussions »

Description

Transgenomic, Inc. provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. The Company also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Its products and services are categorized as Instrument Related Business and Laboratory Services. It has sold its products to customers in over 50 countries. Customers include numerous academic and medical institutions in the United States and abroad. In addition, its customers include a number of United States and foreign pharmaceutical, biotech and commercial companies.

Officers and directors

Rodney S. Markin M.D., Ph.D.
Chairman of the Board
Age: 52
Craig J. Tuttle
President, Chief Executive Officer, Director
Age: 57
Debra A. Schneider
Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 50
Eric Kaldjian M.D.
Chief Scientific Officer
Age: 47
Jeffrey L. Sklar M.D., Ph.D.
Director
Age: 61
Gregory T. Sloma
Director
Age: 57
Antonius P. Schuh Ph.D.
Director
Age: 40
Michael B. McNulty
Director